Botulinum Toxin Injection Targets Sensory Nerves for COPD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation and elevated levels of neuroexcitatory peptides such as Substance P and CGRP, leading to persistent airway inflammation and tissue destruction, which existing treatments only partially address, with limitations in specificity and safety.
Innovation Solution
Administering botulinum toxin via subcutaneous or intradermal injection around specific nerves, such as trigeminal, cervical, thoracic, lumbar, and sacral nerves, to target unmyelinated sensory nerves and reduce overproduction of Substance P and CGRP, thereby alleviating COPD symptoms without affecting normal glutamate and CGRP production or function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If monoclonal antibodies are used to eliminate all glutamate, CGRP, and Substance P, then neuroexcitatory effects are reduced, but normal physiological functions are disrupted causing disastrous side effects
Solution Approach 1:
The patent applies local quality by using botulinum toxin to specifically target and reduce Substance P and CGRP in the lungs and airways where they cause COPD pathology, while preserving glutamate and normal Substance P/CGRP functions in other parts of the body. This localized action allows selective reduction of harmful neuroexcitatory effects without disrupting normal physiological functions elsewhere.
Solution Approach 2:
The patent uses botulinum toxin as an intermediary substance that selectively inhibits the release of specific neuroexcitatory peptides (Substance P and CGRP) from sensory nerves in the lungs. This intermediary approach allows indirect reduction of harmful effects while preserving direct neuronal function and other neurotransmitter systems.
2Object-affected harmful factors
If receptor antagonists are used to block glutamate, Substance P, and CGRP everywhere, then neuroexcitatory effects are reduced, but normal physiological functions are blocked causing overreduction in areas with normal levels
Solution Approach 1:
The patent applies local quality by using botulinum toxin to specifically target and reduce Substance P and CGRP in the lungs and airways where they cause COPD pathology, while preserving glutamate and normal Substance P/CGRP functions in other parts of the body. This localized action allows selective reduction of harmful neuroexcitatory effects without disrupting normal physiological functions elsewhere.
3Object-affected harmful factors
If high doses of botulinum toxin are used to reduce Substance P and CGRP, then COPD symptoms are alleviated, but motor side effects increase
Solution Approach 1:
The patent applies local quality by administering botulinum toxin specifically to target sensory nerves in the lungs and airways, where it selectively reduces Substance P and CGRP release. This localized application ensures that motor nerves and acetylcholine release are not affected, thereby alleviating COPD symptoms without causing motor side effects.
Solution Approach 2:
The patent uses partial action by employing low doses of botulinum toxin (1-100 units) that are sufficient to inhibit Substance P and CGRP release in sensory nerves but insufficient to affect motor nerve function. This partial inhibition approach achieves therapeutic effect while avoiding excessive suppression of normal physiological functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively lowers blood levels of Substance P and CGRP, reducing COPD symptoms and inflammation, with minimal motor side effects and the potential for reduced medication use, as demonstrated by case studies showing improved breathing and reduced medication dependency.
Implementation Method 1
Botulinum toxins cleave and destroy a protein called synaptosomal nerve-associated protein 25 ('SNAP25') and/or synaptobrevin (also called vesicle-associated membrane protein ['VAMP'])
Data Source
AI summary
Botulinum toxin for use in treating chronic obstructive pulmonary disease (COPD) in a patient in need thereof is provided. The treatment comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient.